Pages that link to "Q70891287"
Jump to navigation
Jump to search
The following pages link to Randomized trials between behenoyl cytarabine and cytarabine in combination induction and consolidation therapy, and with or without ubenimex after maintenance/intensification therapy in adult acute myeloid leukemia. The Japan Leukemia Study Group (Q70891287):
Displaying 34 items.
- Maintenance therapy in acute myeloid leukemia: an evidence-based review of randomized trials (Q30249246) (← links)
- CD13 is a therapeutic target in human liver cancer stem cells (Q30496324) (← links)
- Idarubicin plus behenoyl cytarabine and 6-thioguanine compares favorably with idarubicin plus cytarabine-based regimen for children with previously untreated acute myeloid leukemia: 10-year retrospective, multicenter study in Korea (Q33565514) (← links)
- Morphological diagnoses of the Japan adult leukemia study group acute myeloid leukemia protocols: central review (Q34261370) (← links)
- A randomized comparison of 4 courses of standard-dose multiagent chemotherapy versus 3 courses of high-dose cytarabine alone in postremission therapy for acute myeloid leukemia in adults: the JALSG AML201 Study (Q34626054) (← links)
- DNMT3A Mutational Status Affects the Results of Dose-Escalated Induction Therapy in Acute Myelogenous Leukemia (Q34667618) (← links)
- Prognostic Relevance of Cytokine Receptor Expression in Acute Myeloid Leukemia: Interleukin-2 Receptor α-Chain (CD25) Expression Predicts a Poor Prognosis (Q35777301) (← links)
- Improving nucleoside analogs via lipid conjugation: Is fatter any better? (Q36706248) (← links)
- Clinical studies of acute myeloid leukemia in the Japan Adult Leukemia Study Group (Q38031146) (← links)
- Isodicentric chromosome 21: a novel aberration in acute myeloid leukemia (Q38501562) (← links)
- Prognostic Significance of NRAS Gene Mutations in Children with Acute Myelogenous Leukemia (Q40055219) (← links)
- Comparison of the effects of early intensified induction chemotherapy and standard 3+7 chemotherapy in adult patients with acute myeloid leukemia (Q42377773) (← links)
- Allogeneic stem cell transplantation versus chemotherapy as post-remission therapy for intermediate or poor risk adult acute myeloid leukemia: results of the JALSG AML97 study (Q43197991) (← links)
- Randomized trial of response-oriented individualized versus fixed-schedule induction chemotherapy with idarubicin and cytarabine in adult acute myeloid leukemia: the JALSG AML95 study (Q43200906) (← links)
- Mutations of the epigenetics-modifying gene (DNMT3a, TET2, IDH1/2) at diagnosis may induce FLT3-ITD at relapse in de novo acute myeloid leukemia (Q43579359) (← links)
- Close correlation of 1-beta-D-arabinofuranosylcytosine 5'-triphosphate, an intracellular active metabolite, to the therapeutic efficacy of N(4)-behenoyl-1-beta-D-arabinofuranosylcytosine therapy for acute myelogenous leukemia (Q43747889) (← links)
- Prognostic significance of the null genotype of glutathione S-transferase-T1 in patients with acute myeloid leukemia: increased early death after chemotherapy (Q43882746) (← links)
- Intensified daunorubicin in induction therapy and autologous peripheral blood stem cell transplantation in postremission therapy (Double-7 protocol) for adult acute myeloid leukemia (Q44269630) (← links)
- Interaction between leukemic-cell VLA-4 and stromal fibronectin is a decisive factor for minimal residual disease of acute myelogenous leukemia (Q44536202) (← links)
- Dual mutations in the AML1 and FLT3 genes are associated with leukemogenesis in acute myeloblastic leukemia of the M0 subtype (Q44619780) (← links)
- Mutations in the receptor tyrosine kinase pathway are associated with clinical outcome in patients with acute myeloblastic leukemia harboring t(8;21)(q22;q22). (Q46497558) (← links)
- A randomized, postremission comparison of four courses of standard-dose consolidation therapy without maintenance therapy versus three courses of standard-dose consolidation with maintenance therapy in adults with acute myeloid leukemia: the Japan A (Q46801643) (← links)
- Phase I trial of FLAGM with high doses of cytosine arabinoside for relapsed, refractory acute myeloid leukemia: study of the Japan Adult Leukemia Study Group (JALSG). (Q46869262) (← links)
- Randomized comparison of fixed-schedule versus response-oriented individualized induction therapy and use of ubenimex during and after consolidation therapy for elderly patients with acute myeloid leukemia: the JALSG GML200 Study (Q51336746) (← links)
- Importance of c-kit mutation detection method sensitivity in prognostic analyses of t(8;21)(q22;q22) acute myeloid leukemia (Q53245841) (← links)
- Very Late Relapse of Acute Promyelocytic Leukemia 17 Years after Continuous Remission. (Q64975122) (← links)
- Allogeneic bone marrow transplantation improves the outcome of de novo AML with trilineage dysplasia (AML-TLD) (Q73166084) (← links)
- Characteristics of t(8;21) acute myeloid leukemia (AML) with additional chromosomal abnormality: concomitant trisomy 4 may constitute a distinctive subtype of t(8;21) AML (Q73230835) (← links)
- Clinicopathologic characteristics of leukemia in Japanese children and young adults (Q74297339) (← links)
- Cooperative oncology groups in Japan: experience from the Japan Adult Leukemia Study Group (Q77337904) (← links)
- Analysis of bacteremia/fungemia and pneumonia accompanying acute myelogenous leukemia from 1987 to 2001 in the Japan Adult Leukemia Study Group (Q83147589) (← links)
- Randomized study of induction therapy comparing standard-dose idarubicin with high-dose daunorubicin in adult patients with previously untreated acute myeloid leukemia: the JALSG AML201 Study (Q84698071) (← links)
- Infectious complications in adults undergoing intensive chemotherapy for acute myeloid leukemia in 2001-2005 using the Japan Adult Leukemia Study Group AML201 protocols (Q88962446) (← links)
- Inhibition of LTA4H by bestatin in human and mouse colorectal cancer (Q91992239) (← links)